S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
NASDAQ:PRDS

Pardes Biosciences (PRDS) Stock Forecast, Price & News

$2.16
0.00 (0.00%)
(As of 09/12/2023)
Compare
Today's Range
$2.16
$2.16
50-Day Range
$2.09
$2.16
52-Week Range
$0.75
$3.93
Volume
400 shs
Average Volume
359,530 shs
Market Capitalization
$133.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50

PRDS stock logo

About Pardes Biosciences (NASDAQ:PRDS) Stock

Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to treat and prevent viral diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California. As of August 31, 2023, Pardes Biosciences, Inc. operates as a subsidiary of MediPacific, Inc.

PRDS Price History

PRDS Stock News Headlines

Pardes Biosciences Announces Closing of Tender Offer
Better Than Oil Stocks?
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Pardes Biosciences Seeking Strategic Alternatives
Pardes Biosciences (PRDS) Receives a Hold from SVB Securities
Pardes Biosciences Inc.
SVB Securities downgrades Pardes Biosciences (PRDS) to a Hold
See More Headlines
Receive PRDS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pardes Biosciences and its competitors with MarketBeat's FREE daily newsletter.

PRDS Company Calendar

Last Earnings
8/04/2023
Today
9/30/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRDS
Fax
N/A
Employees
57
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.50
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+62.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Net Income
$-96,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.51 per share

Miscellaneous

Free Float
36,711,000
Market Cap
$133.95 million
Optionable
Not Optionable
Beta
0.42
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Thomas G. Wiggans (Age 71)
    CEO & Chairman
    Comp: $859.4k
  • Dr. Uri A. Lopatin M.D. (Age 51)
    Founder & Director
    Comp: $786.96k
  • Ms. Heidi Henson CPA (Age 57)
    Chief Financial Officer
    Comp: $564.6k
  • Ms. Elizabeth Haber Lacy J.D. (Age 56)
    Gen. Counsel & Corp. Sec.













PRDS Stock - Frequently Asked Questions

Should I buy or sell Pardes Biosciences stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pardes Biosciences in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PRDS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRDS, but not buy additional shares or sell existing shares.
View PRDS analyst ratings
or view top-rated stocks.

What is Pardes Biosciences' stock price forecast for 2023?

4 equities research analysts have issued 12 month target prices for Pardes Biosciences' shares. Their PRDS share price forecasts range from $2.00 to $5.00. On average, they anticipate the company's stock price to reach $3.50 in the next year. This suggests a possible upside of 62.0% from the stock's current price.
View analysts price targets for PRDS
or view top-rated stocks among Wall Street analysts.

How have PRDS shares performed in 2023?

Pardes Biosciences' stock was trading at $1.69 on January 1st, 2023. Since then, PRDS stock has increased by 27.8% and is now trading at $2.16.
View the best growth stocks for 2023 here
.

When is Pardes Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our PRDS earnings forecast
.

How were Pardes Biosciences' earnings last quarter?

Pardes Biosciences, Inc. (NASDAQ:PRDS) released its quarterly earnings data on Friday, August, 4th. The company reported ($0.18) EPS for the quarter.

What is Pardes Biosciences' stock symbol?

Pardes Biosciences trades on the NASDAQ under the ticker symbol "PRDS."

How do I buy shares of Pardes Biosciences?

Shares of PRDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pardes Biosciences' stock price today?

One share of PRDS stock can currently be purchased for approximately $2.16.

How much money does Pardes Biosciences make?

Pardes Biosciences (NASDAQ:PRDS) has a market capitalization of $133.95 million. The company earns $-96,630,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis.

How can I contact Pardes Biosciences?

Pardes Biosciences' mailing address is 900 LARKSPUR LANDING CIRCLE SUITE 150, SAN FRANCISCO CA, 94939. The official website for the company is www.pardesbio.com. The company can be reached via phone at 415-649-8758.

This page (NASDAQ:PRDS) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -